To present up to date evidence on the pathogenicity of low-density lipoprotein receptor (LDLR) variants and to propose a strategy that is suitable for implementation in the clinical work-up of familial hypercholesterolaemia.
INTRODUCTION
More than 90% of mutations described in patients with familial hypercholesterolaemia are found in the low-density lipoprotein receptor (LDLR) gene [1] [2] [3] [4] . Untreated familial hypercholesterolaemia can give rise to marked premature coronary artery disease [5] . Mutations in the genes coding for apolipoprotein B (APOB) and proprotein convertase subtilisin/kexin type 9 (PCSK9) are rare causes of familial hypercholesterolaemia (<10%). The molecular diagnosis of this disorder is required to obtain diagnostic certainty and to perform accurate family screening. However, care should be taken interpreting the result of the genetic diagnosis. In theory, the clinical diagnosis can only be confirmed when a mutation is found and then proven by functional studies to affect LDL metabolism. Variants that lead to the introduction of an early stop codon (nonsense and frameshift alterations) and large rearrangements are known to have a deleterious effect on the function of the LDLR protein. Therefore these mutations are considered to be pathogenic variants without need of further evidence [6] . Nevertheless, the majority of the genetic alterations associated with familial hypercholesterolaemia are in neither of these categories, similar to the majority of other genetic diseases. To overcome this difficulty, the American College of Medical Genetics (ACMG) issued in 2015 [7 && ] guidelines for the functional classification of genetic variants that should be taken into account before making a genetic diagnosis. In these guidelines, variants are classified as 'pathogenic', 'likely pathogenic', 'variants of unknown significance' (VUS), 'likely benign' and 'benign'. Genetic variants are classified based on a number of criteria; before a variant is considered a disease-causing mutation, support is, for instance, required from structural analyses, evidence from functional studies and in-silico analyses. Following these guidelines, only carriers of variants from the pathogenic and likely pathogenic classes should see their clinical diagnosis confirmed; the remaining patients need to await functional confirmation of the variant's pathogenicity. The purpose of this review is to present up to date evidence on the pathogenicity of LDLR variants and to propose a strategy that is suited for implementation in the clinical work-up of familial hypercholesterolaemia.
GENETIC DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLAEMIA
The genetic diagnosis of familial hypercholesterolaemia has been performed, until now, by the study of the all exons and adjacent splicing regions of the LDLR gene by PCR amplification followed by Sanger sequencing, search for large rearrangements by Multiplex Ligation-dependent Probe Amplification (MLPA) analysis and the study of one (part of exon 26) or two fragments (part of exon 26 and part of exon 29) of APOB gene [2, [8] [9] [10] [11] , also by PCR amplification and Sanger sequencing. PCSK9 gene is only studied in some laboratories [12, 13] . However, nextgeneration sequencing (NGS) strategies are changing the genetic diagnosis of familial hypercholesterolaemia, and in the near future, it is expected that, whenever possible, laboratories will be using target sequencing with the complete study of all three familial hypercholesterolaemia genes -LDLR, APOB and PCSK9, and possibly familial hypercholesterolaemia gene phenocopies will be added to such panels (LIPA, APOE, LDLRAP1 and ABCG5/8) because they do not represent a great increase in the overall cost and allow better stratified diagnosis [14] .
LOW-DENSITY LIPOPROTEIN RECEPTOR VARIANTS UPDATE
A compilation of the data available in three public available databases [Leiden Open (source) Variation Database (LOVD)2, LOVD3 and Human Gene Mutation Database] and a bibliography search of the past 10 years up to December 2015 lead to the identification of a total of 1891 variants in LDLR described as causing familial hypercholesterolaemia [15 && ], but ACMG criteria were never applied to majority of variants in these databases. For this analysis, reference sequence NM_000527.4, NG_009060.1 and assembly GRCh37 were used. We now have classified the 1891 reported variants following ACMG guidelines in the five categories (Table 1) , and over 40% need further evidence before they can be confirmed as disease-causing mutations. These numbers do not include reported variants with a minor allele frequency (MAF) greater than 5%. The spectrum of variants in the LDLR identified in patients with clinical familial hypercholesterolaemia is still increasing as novel variants keep on being reported. Increasing awareness of the disorder and access to modern DNA sequence facilities contribute to the growing databases of LDLR variants. For instance, in 2016, 31 novel alterations in the LDLR have been reported mainly in the German, Poland and South African populations [16] [17] [18] Table 2 ). The majority of the VUS are classified as such because they do not have functional studies and represent 42% of all variants reported to be cause of familial hypercholesterolaemia. These variants should be the top priority for in-vitro functional assessment. In fact, only 174 out of the 1891 LDLR putative mutations have ever undergone a complete functional study in heterologous cells, which is one of the better suited assays to characterize LDLR putative mutations [27 && ], or studies on familial hypercholesterolaemia homozygote patient cells (lymphoblast or fibroblasts) have been performed (Table 3 ). Due to the high level of evidence obtained in these studies, these were considered level 1
KEY POINTS
More than 1800 LDLR variants have been described in clinical familial hypercholesterolaemia patients.
About 50% of these variants need further evidence to be considered pathogenic.
American College of Medical Genetics helps on variant classification, but a large number still need functional evaluation.
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Establishment of functional studies for these variants is of utmost importance for familial hypercholesterolaemia diagnosis and to prevent confusion in the physician's office. studies (Table 4 ). Other types of functional studies that do add evidence to the variant pathogenicity, but are not completely informative, have been published for another 85 variants (Table 3) . These were considered level 2 studies and include, for example, analysis of number of transcripts for putative slicing variants, but without transcript quantification, and assays performed with cells of familial hypercholesterolaemia heterozygote patients (Table 4 ). This means that less than 15% of all variants described have any kind of functional evidence on which they can be classified as a disease-causing mutation.
FUNCTIONAL STUDIES FOR LOW-DENSITY LIPOPROTEIN RECEPTOR MUTATIONS
Pathogenic LDLR mutations can affect different parts of the LDL receptor cycle: protein synthesis; protein maturation; expression at cell surface and correct insertion in cell membrane; LDL binding; internalization; recycling. The most severe alterations are those that lead to no protein production. These are usually mutations affecting protein expression and synthesis (e.g. when an early stop codon is introduced or a promoter mutation) and also large rearrangements, because no functional protein is produced from those alleles (null allele). Also, a number of missense mutations have less than 2% LDL receptor activity in in-vitro assays (Table 5) , and for this reason are classified as null alleles.
The present-day functional characterization of variants found in LDLR, APOB or PCSK9 genes is very similar to the ones developed by Brown and Goldstein in order to characterize the LDL receptor cycle comparing LDL receptor activity in normal conditions and in presence of specific mutations. The major difference is that radioactive iodine is replaced by fluorescent labeling of the LDL particle to follow the cycle [28] .
The use of flow cytometry allows to follow this fluorescent labelled LDL and to determine the LDLR activity. Another difference is that familial hypercholesterolaemia heterozygote patient cells are no longer used, since the 'normal copy' of the LDLR gene interferes with the mutant allele expression leading to conflicting results [3, 27 && ]. However, true familial hypercholesterolaemia homozygote patient cells are the best human models for functional studies, mostly used in the Dallas collection [29] .
Putative point mutation and in-frame deletions/insertions
In general, to assess LDLR putative mutations, a plasmid containing the LDLR wild-type cDNA (usually pcDNA3) is mutated by in-vitro mutagenesis and transfect into appropriate cell lines (usually CHO-ldlA7 cell line that has been altered to have only residual LDLR activity). After transfecting these cells with the mutated plasmid, the cell line expresses the mutant receptor enabling analyses of the LDLR cycle by following the labelled LDL and observe whether it binds, internalizes and recycles to cell surface or it fails in any of these stages, which leads to the exact characterization of the cellular defect. Immunoblotting (western blot) complements all these experiments to test if the LDLR mutant was able or not to go from the precursor to the mature form. If a defect in maturation occurs, the mutant LDLR is retained in the endoplasmic reticulum (ER) and can be seen by confocal microscopy. Finally, flow cytometry, using specific antibodies, will show if the mutant LDLR is expressed at cell surface or not. Additional experiments can determine if the defect is in the recycling pathway (kinetic studies) [20 && ]. Taken together, these methods allow us to determine if the mutant LDLR is retained in the ER (confocal microscopy studies); not able to form the mature form of the protein (western blot); not expressed on the cell surface (flow cytometry studies); not able to bind and internalize LDL (flow cytometry studies); not able to recycle to the cell surface (kinetic studies). Recently, a new class of mutations has been described by Ström et al. [22 && ], which is referred to as defective positioning of LDLR on the basolateral cell surface. This can be studied by transient transfection of liver hepatocellular cells with mutant LDLR plasmids and subsequent study of the mutant LDL receptors in cell lysates in media by western blot analysis [22 && ]. These experiments enable characterization of the cellular defect and clarify how these mutants affect LDLR activity. If an alteration leads to very small residual (<2%) or absent LDLR activity, the alteration is considered to produce a null allele. This means that no functional protein is produced and the patient phenotype is usually severe [3, 36, 37] . On the contrary, if some residual LDLR activity (!2%) is detected, the alteration results in a defective allele. The degree to which the mutation affects the LDLR activity can determine patient's phenotype as demonstrated previously [20 && ]. However, LDLR activity in an individual can be influenced by the environment and/or other alterations in lipid metabolism genes [38] . Therefore, the relationship between LDLR activity and phenotype is not always straightforward. The case of the mutant c.12146C>T, p.(Arg406Trp) is of great interest [20 && ]. Carriers of this variant have a highly variable expression, resulting in very mild to severe phenotypes. The functional study unraveled the reason of this high variability in phenotypes. The cell expression, binding and internalization were about 60%, which implies that this mutant allele has a substantial residual LDLR activity. In addition, the microscopy studies revealed that these receptors are expressed at FA, functional studies; LDLR, low-density lipoprotein receptor.
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Total not considered 94 Table 5 . Missense LDLR variants proved so far to produce an LDL receptor with less than 2% activity cell surface to a certain level [20 && ]. This LDLR activity can be sufficient for LDL clearance in case of an adequate healthy lifestyle, but it is dysfunctional in persons who do not adhere to a diet with fat restriction and exercise recommendations. Based on the functional insights from this variant, the clinician might be able to tailor the therapy with a strong recommendation on lifestyle changes, and, if the patient complies, perhaps a low instead of a highdosage statin is sufficient. This was exemplified by the phenotype presented by a number of these mutation carriers [20 && ].
Putative splicing variants
Although the majority of LDLR variants are studied with the methods presented above, putative splicing variants can be studied with less laborious methodology which has been described previously [26] . Since putative splicing variants are suspected to interfere with correct mRNA splicing, it is possible to study a patient's mRNA from lymphocytes to check if one or more transcripts are produced. Several variants have been characterized this way . But, whereas this method is sufficient to detect if alternative splicing occurs, it does not quantify its effect, so we do not know, for example, if 80 or 20% of aberrant transcripts are present. This is important, because it will affect the amount of normal protein that is produced, and ultimately LDLR activity. For instance, if only 20% or less of aberrant transcripts are detected, this alteration may be classified as benign, because at least 80% of LDLR activity is expected and 80% is the minimum considered to be necessary for normal LDL clearance [20 && ,42,43] . In fact, there are patients with splicing mutations who do present with a severe phenotype, whereas other carriers of such variants have mild phenotypes [39, 40] . We postulate that the difference between these two different groups has to do with transcript quantification that can be determined by real-time PCR. Again, functional studies can help understand the phenotype and add additional information to optimize patient treatment.
It cannot be forgotten that nucleotide changes in the first or the last three nucleotides of an exon can also affect splicing [44] , and in-silico analysis should be performed for these kinds of alterations, and, whenever possible, in-vitro analysis as well. Since the number of transcripts is easily obtained by the analysis of the mRNA, these analyses could be performed in nearly all laboratories [9, 26] . Several variants in these positions have been found all over the world [22 && ,26,45-48] . For example, in the Portuguese familial hypercholesterolaemia study, one case was found in whom the nucleotide change c.2389G>A was predicted to change p.(Val776Leu), but when the splicing machinery was studied, skipping of exon 16 was observed introducing a premature stop codon p.Ala771Valfs Ã 17 [26] . Also, although rare, synonymous alterations can cause splicing defects. The first of these cases has been described in the United Kingdom [49] , where a patient was found to have the alteration c.1216C>A, predicted to cause p.(Arg406Arg). Analysis of mRNA from the patient's cells showed that the mutation introduces a new splice site, which is used to the exclusion of the natural splice site and causes a deletion of 31 bp from the mRNA, predicted to introduce premature termination four codons after Arg406 (p.Ser397Thrfs Ã 6). In 2008, a Dutch group published another synonymous variant, c.621C>G, p.(Gly207Gly), as cause of splicing defect [50] . A novel synonymous variant c.1813C>T, p.(Leu605-Leu) has been recently characterized as having an effect on splicing [51 & ], introducing also a premature stop codon.
Another interesting alteration has been described as causing aberrant splicing -c.2140 þ 86C>G 86C>G (intron 14) -which activated a cryptic splice site. This alteration causes the insertion of 81 bp in LDLR mRNA and encodes for an in-frame insertion of 27 amino acids in the LDLR, preventing the receptor from leaving the endoplasmic reticulum, probably because of misfolding of the protein. This case highlights the importance of looking for mutations in sites not commonly studied specially in patients without an identifiable mutation in the three genes causing familial hypercholesterolaemia, but with a phenotype very suggestive of familial hypercholesterolaemia [39] .
Putative regulatory variants
Putative regulatory variants can be studied by luciferase assays, and 17 out of the 42 described variants have been characterized this way [19 && ,52-57] . The luciferase assay is based upon the bioluminescent measurement of firefly luciferase. Briefly, the promoter region is cloned into a plasmid and the mutants are created by sitedirected mutagenesis. Wild-type and mutant plasmids are then transfected into a specific cell line and let to grow. Cells are lysed and luciferase activity is then determined using a reporter assay measured in a luminometer.
CONCLUSION
More than 1800 variants have been described in the LDLR of patients with a clinical diagnosis of familial hypercholesterolaemia; however, less than 15% have functional evidence supporting pathogenicity. Considering that nonsense, frameshift and large rearrangements have a deleterious effect on a protein, there are still about 1000 variants that need functional characterization. Without definite confirmation of the effect on the expression and activity of the LDLR, reporting these variants as part of a patient's clinical diagnosis carries the risk that the inference of causality might need to be withdrawn in a later stage. The latest ACMG guidelines are a valuable tool for variant classification in order to be able to report the molecular findings to clinicians. However, even when applying the ACMG classification, almost 800 variants need further evidence to be considered pathogenic or likely pathogenic. Establishment of functional studies for these variants is of utmost importance for the diagnosis and to prevent confusion in the physician's office about it.
